'The marvellous harmony of the nervous parts': The origins of multiple sclerosis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 4, Issue 4, 2004, Pages 346-354

  Compston, Alastair ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Epidemiology; Genetics; MHC; Mitochondrial haplogroups; Multiple sclerosis; Neuromyelitis optica; Optico spinal; TH1; TH2; William Croone

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR;

ALLELE; CELL LINEAGE; CONFERENCE PAPER; CULTURAL FACTOR; DEMYELINATING DISEASE; DEMYELINATION; EPIDEMIOLOGICAL DATA; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE CELL PLASTICITY; NERVE CONDUCTION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOGENESIS; POPULATION GENETICS; PROTEIN FUNCTION; RACE DIFFERENCE; RELAPSE; REMISSION; REMYELINIZATION; RISK FACTOR;

EID: 4243128354     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.4-4-346     Document Type: Conference Paper

References (60)

1. [Croone W] Willis T. Verklaringe over de oorsaeck van het bewegen der spieren. Amsterdam: Schagen, 1667:45.
2. Firth D (ed). The Case of Augustus D'Este. Cambridge: Cambridge University Press, 1948.
3. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120:2149-57.
4. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001;49:470-6.
5. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002;125:338-49.
6. Coles AJ, Le Page E, Cox AL, Goodin DS et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy in relapsing-remitting and secondary progressive disease. Ann Neurol (in press).
7. Wilkins A, Majed H, Layfield R, Compston A et al. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci 2003;23:4967-74.
8. Lucchinetti C, Brück W, Parisi J, Scheithauer B et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
9. Sutherland JM. Observations on the prevalence of multiple sclerosis in northern Scotland. Brain 1956;79:635-54.
10. Poser CM. The dissemination of multiple sclerosis: A Viking Saga? A historical essay. Ann Neurol 1994;36:S231-S234.
11. Roberts DF. Who are the Orcadians? Anthrop Anzeiger 1986;44:93-104.
12. Devic E. Myelite subaigue compliquee de nevrite optique. Bull Med (Lyon) 1894;35:18-30.
13. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.
14. Lucchinetti CF, Mandler RN, McGavern D, Bruck W et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61.
15. Osuntokun BO. Neurological disorders in Nigeria. In: JD Spillane (ed), Tropical neurology. London: Oxford University Press, 1973:161-90.
16. Dean G, Bhigjee AIG, Bill PLA, Fritz V et al. Multiple sclerosis in black South Africans and Zimbabweans. J Neurol Neurosurg Psychiatry 1994;57:1064-69.
17. Modi G, Mochan A, Modi M, Saffer D. Demyelinating disorder of the central nervous system occurring in black South Africans. J Neurol Neurosurg Psychiatry 2001;70:500-5.
18. Jain S, Maheshwari MC. Multiple sclerosis: Indian experience in the last thirty years. Neuroepidemiol 1985;4:96-107.
19. Tan CT. Multiple sclerosis in Malaysia. Arch Neurol 1988;45;624-7.
20. Kurzke JF, Park CS, Oh SJ. Multiple sclerosis in Korea. Clinical features and prevalence. J Neurol Sci 1968;6:463-81.
21. Yu YL, Woo E, Hawkins BR, Ho HC, Huang CY. Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989;112:1445-567.
22. Okinaka S, Tsubaki T, Kuroiwa Y, Toyokura Y et al. Multiple sclerosis and allied diseases in Japan. Clinical characteristics. Neurology 1958;8:756-63.
23. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis; comparison between British and Japanese patients. J Neurol Sci 1981;49:253-71.
24. Mirsattari SM, Johnston JB, McKenna R, Del Bigio MR et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology 2001;56:317-23.
25. Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, de Almeida AM et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002;73:429-35.
26. Cabre P, Heinzlef O, Merle H, Buisson GG et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507-14.
27. Cree BAC, Khan O, Bourdette D et al. Clinical characteristics of multiple sclerosis in African Americans (submitted).
28. Sykes B. The molecular genetics of European ancestry. Phil Trans R Soc Lon 1999;354:131-9.
29. Renfrew C. Genetics and language in contemporary archaelogy, In: Cunliffe B, Davies W, Renfrew C (eds) Archaeology. The widening debate. Oxford: The British Academy/Oxford University Press, 2002: 43-76.
30. Richards M, Corte-Real H, Forster P, Macaulay V et al. Paleolithic and neolithic lineages in the European mitochondrial gene pool. Am J Hum Genet 1996;59:185-203.
31. Herrnstadt C, Elson JL, Fahy E, Preston G et al. Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major Afrian, Asian, and European haplogroups. Am J Hum Genet 2002;70:1152-71.
32. Mayr-Wohlfart U, Paulus C, Hennenberg A, Rodel G. Mitochondrial DNA mutations in multiple sclerosis patients with severe optic involvement. Acta Neurol Scand 1996;94:167-71.
33. Kalman B, Li S, Chatterjee D, O'Connor J et al. Large scale screening of the mitochondrial DNA reveals no pathogenic mutations but a haplotype associated with multiple sclerosis in Caucasians. Acta Neurol Scand 1999;99:16-25.
34. Reynier P, Penisson-Besnier I, Moreau C, Savagner F et al. mtDNA haplogroup J: a contributing factor of optic neuritis. Eur J Hum Gen 1999;7:404-6.
35. Otegui D, Saenz A, Martinez-Zabaleta M, Villoslada P et al. Mitochondrial haplogroups in Basque multiple sclerosis patients. Multiple Sclerosis (in press).
36. Harding AE, Sweeney MG, Miller DH, Mumford CJ et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115: 979-89.
37. Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG et al. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995;118:319-37.
38. Kellar-Wood H, Robertson N, Govan GG, Harding AE, Compston DAS. Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann Neurol 1994b;36:109-12.
39. Kalman B, Rodriguez-Valdez JL, Bosch U, Lublin FD. Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Multiple Sclerosis 1997;2:279-82.
40. Cock H, Mandler R, Ahmed W, Schapira AH. Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 1997;62:85-7.
41. Kalman B, Mandler RN. Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations, but polymorphisms also found in association with multiple sclerosis. Ann Neurol 2002;51:661-2.
42. Nishimura M, Obayashi H, Ohta M, Uchiyama T et al. No association of the 11778 mitochondrial DNA mutation and multiple sclerosis in Japan. Neurology 1995;45:1333-4.
43. Hwang IM, Chang BL, Park SS. Leber's hereditary optic neuropathy mutations in Korean patients with multiple sclerosis. Ophthalmologica 2001;215:398-400.
44. Heyer E. Mitochondrial and nuclear genetic contribution of female founders to a contemporary population in Northeast Quebec. Am J Hum Genet 1995;56:1450-5.
45. Gabriel SB, Schaffner SF, Nguyen H, Moore JM et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
46. de Vries RR, Khan M, Bernini LF, van Loghem E, van Rood JJ. Genetic control of survival in epidemics. J Immunogenet 1979;6:271-87.
47. Le Soeuf PN, Goldblatt J, Lynch NR. Evolutionary adaptation of inflammatory immune responses in human beings. Lancet 2000;356: 242-4.
48. The MHC Sequencing Consortium. Complete sequence and gene map of a human major histompatibility complex. Nature 1999;401:921-3.
49. Mungall AJ, Palmer SA, Sims SK, Edwards CA et al. The DNA sequence and analysis of human chromosome 6. Nature 2003;425:805-11.
50. GAMES and the Transatlantic Multiple Sclerosis genetics cooperative. A meta-analysis of whole genome linkage screens in multiple sclerosis. J Neuroimmunol 2003;143:39-46.
51. Mitra DK, Rajalingam R, Taneja V, Bhattacharyya BC, Mehra NK. HLA-DR polymorphism modulates the cytokine profile of Mycobacterium leprae HSP-reactive CD4+ T cells. Clin Immunol Immunopathol 1997;82:60-7.
52. Wang S, Sdrulla AD, Disibio G, Bush G et al. Notch receptor activation inhibits oligdenrocyte differentiation. Neuron 1998;21:63-75.
53. John GR, Shankar SL, Shafit-Zagardo B, Massimi A et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002;8:1075-6.
54. Lang HLE, Jacobsen H, Ikemizu S, Andersson C et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nature Immunol 2002;3:940-43.
55. McGeogh DJ. Molecular evolution of the alpha-herpesvirinae. Phil Trans R Soc Lond 2001;356:421-35.
56. Compston DAS, Vakarelis BN, Paul E, McDonald WI et al. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986;109:325-44.
57. Martyn CN, Cruddas M, Compston DAS. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:167-8.
58. Kira J-I. Multiple sclerosis in the Japanese population. Lancet Neurology 2003;2:117-27.
59. Cosnett JE. Multiple sclerosis and neuromyelitis optica in tropical and subtropical countries. Med Hypoth 1981b;7:61-3.
60. Cree BAC, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002;22:105-22.